Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP14 | P50281 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | PTPN5 | P54829 | 3/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | PGK1 | P00558 | 1/20 | 0.45 |
| ▸ | PGK2 | P07205 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11476691 | 0.82 | PGK1 (0.65) | MMP8MMP14CA14PTPN5PGK1 | |
| (3,4-Dichlorophenyl)(Hydroxy)Methylphosphonic Acid SCHEMBL11292374 | 0.82 | PTPN5 (0.63) | MMP8MMP14CA14PTPN5PGK1 | |
| SCHEMBL28980067 | 0.80 | MMP8 (0.47) | MMP8MMP14CA14PTPN5PGK1 | |
| SCHEMBL9301497 | 0.77 | SRC (0.75) | SRCPGK1PGK2LMNASMN1; SMN2 | |
| SCHEMBL4093802 | 0.76 | SRC (0.60) | MMP8MMP14CA14SRCPGK1 | |
| SCHEMBL9450680 | 0.73 | SRC (0.70) | SRCPGK1PGK2 | |
| Water SCHEMBL9146143 | 0.72 | SRC (0.56) | MMP8MMP14CA14SRCPGK1 | |
| SCHEMBL2654115 | 0.70 | AHR (0.50) | ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL2171583 | 0.70 | SRC (0.65) | MMP8MMP14CA14PTPN5SRC | |
| SCHEMBL5936840 | 0.69 | SRC (0.62) | CA14SRCPGK1PGK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | GLUL, GLS2, ASNS | MMP8 3564/4885MMP14 2948/4885CA14 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.